Although the Center naturally favors opportunities where liquidation can be affected as expeditiously as possible, we realize that the drug discovery and development process is a lengthy one, and may require seed funding that spans the course of years. Although initial public offerings are always a possible exit event, the most likely exit event for the Center is a buy-out by a venture capital firm or a pharmaceutical company looking for a promising investment.